Biological E aims to produce 100 million doses / month of Corbevax from February 2022

Corbevax, the first protein subunit vaccine developed in India against the virus, received approval today from the Comptroller General of Medicines of India (DGCI), he said.

Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 Corbevax vaccine per month, anticipating more than 100 million doses per month from February 2022, which will allow the company based in the city to deliver 300 million doses as promised to the Center, BE said on Tuesday.

Corbevax, the first protein subunit vaccine developed in India against the virus, received approval today from the Comptroller General of Medicines of India (DGCI), he said.

According to a press release issued soon by the vaccine maker, the company plans to deliver more than a billion additional doses worldwide.

Biological E. Limited plans to complete production at a rate of 75 million doses per month, anticipating more than 100 million doses per month from February 2022. These capacities will allow the Hyderabad-based company to deliver 300 million doses as promised to the government of India, ”he said.

The vaccine was developed by Biological E. Limited in collaboration with the Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine (Baylor) in Houston, Texas.

Mahima Datla, Managing Director of BE limited, said: “Over the years, we have worked to make quality vaccines and pharmaceuticals accessible to families around the world. In this context, we decided to develop an affordable and effective COVID-19 vaccine. It has now become a reality.

Corbevax has completed two Phase III clinical trials involving more than 3,000 subjects aged 18 to 80 at 33 study sites across India. The vaccine has been shown to be safe, well tolerated and immunogenic, the company said.

In the pivotal phase III study conducted with an endpoint of immunogenic superiority, Corbevax demonstrated a superior immune response compared to the Covishield vaccine when evaluated for geometric mean titers (GMT) of neutralizing antibodies ( nAb) against the Ancestral-Wuhan strain and the globally dominant Delta variant, the statement said.

“Our scientists at Texas Children’s Hospital and Baylor College of Medicine are delighted to assist in the development of this vaccine, possibly the first covid vaccine specifically designed for global health,” Peter Hotez, Professor and Dean of the National Baylor School of Tropical Medicine. and co-director of the Texas Children’s Hospital Center for Vaccine Development said.

Financial Express is now on Telegram. Click here to join our channel and stay up to date with the latest news and updates from Biz.


Source link

Comments are closed.